Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aries Stern

Psychiatry Kalamazoo, MI Doctor of Osteopathy

NPI 1699833897 CMS profile 303327

6146 West Main St Suite B, Kalamazoo, MI 49009

Open in the dashboard

General payments

$35,207

289 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aries Stern of Kalamazoo, MI is reported in the CMS Open Payments database as having received $35,207 across 289 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,190 96
2024 General $973 18
2023 General $711 10
2022 General $3,473 34
2021 General $2,606 19
2020 General $8,797 33
2019 General $15,457 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aries Stern
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Aries Stern were reported at $3,190. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Aries Stern Psychiatry median Middle half National median
2019 $15,457 $184 $59–$605 $163
2020 $8,797 $119 $36–$372 $114
2021 $2,606 $143 $43–$576 $132
2022 $3,473 $153 $50–$590 $149
2023 $711 $170 $56–$651 $160
2024 $973 $179 $57–$673 $164
2025 $3,190 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $16,240 50 payments
  2. Teva Pharmaceuticals USA, Inc. $9,679 38 payments
  3. AbbVie, Inc. $2,310 3 payments
  4. Otsuka America Pharmaceutical, Inc. $1,318 41 payments
  5. ITI, Inc. $1,230 26 payments
  6. Alkermes, Inc. $809 21 payments
  7. E.R. Squibb & Sons, L.L.C. $614 18 payments
  8. Axsome Therapeutics, Inc. $552 7 payments
  9. Janssen Pharmaceuticals, Inc $469 10 payments
  10. Neurocrine Biosciences, Inc. $466 6 payments
  11. Other $1,520 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,957 15 payments
  2. Food and Beverage $8,664 256 payments
  3. Consulting Fee $2,400 1 payment
  4. Travel and Lodging $831 11 payments
  5. Education $355 6 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $16,221 48 payments
  2. AUSTEDO $9,124 23 payments
  3. VRAYLAR Neuroscience $2,310 3 payments
  4. LYBALVI Cns $809 21 payments
  5. REXULTI $722 25 payments
  6. CAPLYTA $652 13 payments
  7. LYBALVI Cns $618 10 payments
  8. LYBALVI Cns $618 10 payments
  9. LYBALVI Cns $618 10 payments
  10. ABILIFY MAINTENA $596 16 payments
  11. Other $5,403 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

336

Median for Psychiatry & Neurology: 100

Drug cost

$79,405

Median for Psychiatry & Neurology: $2,986

Branded share of claims

40.2%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 45 $25,501
Rexulti Brexpiprazole Brand 12 $17,703
Vraylar Cariprazine Hcl Brand 12 $17,454
Auvelity Dextromethorphan Hbr/Bupropion Brand 11 $11,619
Oxcarbazepine Generic 18 $1,825
Metformin Er Gastric Metformin Hcl Brand 14 $1,281
Atomoxetine Hcl Generic 14 $1,098
Bupropion Xl Bupropion Hcl Brand 28 $571
Gabapentin Generic 28 $382
Quetiapine Fumarate Generic 23 $335

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $210
$210 — —
LYBALVI
  • Alkermes, Inc. $108
$108 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $100
$100 — —
VRAYLAR
  • AbbVie, Inc. $96
$96 12 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record